Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial.
Chen P, Behre G, Hebert C, Kumar P, Farmer Macpherson L, Graham-Clarke PL, De La Torre I, Nichols RM, Hufford MM, Patel DR, Naegeli AN. Chen P, et al. Among authors: naegeli an. Open Forum Infect Dis. 2022 Apr 7;9(5):ofac172. doi: 10.1093/ofid/ofac172. eCollection 2022 May. Open Forum Infect Dis. 2022. PMID: 35493124 Free PMC article.
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens GR, Tuttle JL, Krueger K, Friedrich S, Durante M, Arora V, Naegeli AN, Schmitz J, Feagan BG. Sandborn WJ, et al. Among authors: naegeli an. Clin Gastroenterol Hepatol. 2022 Jan;20(1):105-115.e14. doi: 10.1016/j.cgh.2020.09.028. Epub 2020 Sep 18. Clin Gastroenterol Hepatol. 2022. PMID: 32950748 Free article. Clinical Trial.
Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease Registry.
Cross RK, Naegeli AN, Harrison RW, Moore PC, Mackey RH, Crabtree MM, Lemay CA, Arora V, Morris N, Sontag A, Kayhan C, Korzenik JR. Cross RK, et al. Among authors: naegeli an. Crohns Colitis 360. 2022 Mar 8;4(3):otac007. doi: 10.1093/crocol/otac007. eCollection 2022 Jul. Crohns Colitis 360. 2022. PMID: 36777423 Free PMC article.
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, Hirai F, D'Haens G, Belin RM, Miller D, Gomez-Valderas E, Naegeli AN, Tuttle JL, Pollack PF, Sandborn WJ. Sands BE, et al. Among authors: naegeli an. Gastroenterology. 2022 Feb;162(2):495-508. doi: 10.1053/j.gastro.2021.10.050. Epub 2021 Nov 5. Gastroenterology. 2022. PMID: 34748774 Clinical Trial.
Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
Dubinsky MC, Jairath V, Feagan BG, Naegeli AN, Tuttle J, Morris N, Shan M, Arora V, Lissoos T, Agada N, Hibi T, Sands BE. Dubinsky MC, et al. Among authors: naegeli an. BMJ Open Gastroenterol. 2023 Mar;10(1):e001115. doi: 10.1136/bmjgast-2023-001115. BMJ Open Gastroenterol. 2023. PMID: 37001911 Free PMC article. Clinical Trial.
54 results